Zhidong Xu, PhD

---

Education

Shanghai Fisheries University, B.S., 1982, Marine Aquaculture
Western Illinois University, M.S., 1986, Biology/Cytogenetics
The University of Texas Medical Branch, Galveston, Ph.D., 1992, Molecular Mutagenesis

---

Professional Experience

• 1986-1988
  Research Assistant, The University of Texas Medical Branch, Galveston, Texas
• 1989-1991
  Co-principal Investigator, Laboratories for Genetic Services, Inc., Houston, Texas
• 1986-1992
  Pre-doctoral Fellow, The University of Texas Medical Branch, Galveston, Texas
• 1992-1993
  Postdoctoral Fellow, Human Genome mapping Center, UCSF
• 1993-1998
  Post-graduate Molecular Biologist, Cardiovascular Research Institute, UCSF
• 1998-2001
  Assistant Researcher, Department of Surgery, UCSF
• 2001-present
  Assistant Adjunct Professor, Department of Surgery, UCSF

---

Honors & Awards

• 1989
  Alexander Hollander Student Travel Award, Environmental Mutagen Society
• 1987-1990
  Scholarships from American Lung Association/San Jacinto Area, Houston, Texas
• 1992
  James E. Beall II Memorial Scholarship, The University of Texas Medical Branch
• 1992
  The Doctor Edward Storrs Reynolds, Jr. Memorial Award, The University of Texas Medical Branch, Galveston, Texas
• 1993
  Walter Travel Fund from American Lung Association, San Francisco

---

Selected Publications

1. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996.
   View on PubMed
2. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3; 379(9818):823-32.
   View on PubMed
3. Li T, Hung MS, Wang Y, Mao JH, Tan JL, Jahan K, Roos H, Xu Z, Jablons DM, You L. Transgenic mice for cre-inducible overexpression of the Cul4A gene. Genesis. 2011 Mar; 49(3):134-41.
   View on PubMed
4. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, You L. Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med. 2011 Feb; 15(2):350-8.
   View on PubMed
5. Li T, Li H, Wang Y, Harvard C, Tan JL, Au A, Xu Z, Jablons DM, You L. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol. 2011 Mar; 223(4):519-30.
   View on PubMed
6. Hung MS, Lin YC, Mao JH, Kim IJ, Xu Z, Yang CT, Jablons DM, You L. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer. PLoS One. 2010; 5(7):e11418.
   View on PubMed
7. More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, Giacomini KM. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther. 2010 Apr; 9(4):1058-69.
   View on PubMed
8. Hung MS, Xu Z, Lin YC, Mao JH, Yang CT, Chang PJ, Jablons DM, You L. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer. 2009; 9:135.
   View on PubMed
9. Chou J, Lin YC, Kim J, You L, Xu Z, He B, Jablons DM. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008 Jul; 30(7):946-63.
   View on PubMed
10. You L, Xu Z, Punchihewa C, Jablons DM, Fujii N. Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription. Mol Cancer Ther. 2008 Jun; 7(6):1633-8.
    View on PubMed
11. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71.
    View on PubMed
12. Clément G, Guilleret I, He B, Yagui-Beltrán A, Lin YC, You L, Xu Z, Shi Y, Okamoto J, Benhattar J, Jablons D. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci. 2008 Jan; 99(1):46-53.
    View on PubMed
13. Shi Y, He B, Kuchenbecker KM, You L, Xu Z, Mikami I, Yagui-Beltran A, Clement G, Lin YC, Okamoto J, Bravo DT, Jablons DM. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer. 2007 Sep 15; 121(6):1175-81.
    View on PubMed
14. Lin YC, You L, Xu Z, He B, Yang CT, Chen JK, Mikami I, Clément G, Shi Y, Kuchenbecker K, Okamoto J, Kashani-Sabet M, Jablons DM. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther. 2007 Apr; 18(4):379-86.
    View on PubMed
15. Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B, Jablons D. Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg. 2007 Mar; 133(3):733-7.
    View on PubMed
16. Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, Guy RK, Jablons DM. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res. 2007 Jan 15; 67(2):573-9.
    View on PubMed
17. Kim JY, Harvard C, You L, Xu Z, Kuchenbecker K, Baehner R, Jablons D. Stathmin is overexpressed in malignant mesothelioma. Anticancer Res. 2007 Jan-Feb; 27(1A):39-44.
    View on PubMed
18. Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I, You L, Xu Z, Lin YC, Clément G, Jablons DM. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun. 2006 Apr 21; 342(4):1228-32.
    View on PubMed
19. Lin YC, You L, Xu Z, He B, Mikami I, Thung E, Chou J, Kuchenbecker K, Kim J, Raz D, Yang CT, Chen JK, Jablons DM. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun. 2006 Mar 10; 341(2):635-40.
    View on PubMed
20. You L, Kim J, He B, Xu Z, McCormick F, Jablons DM. Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect. 2006 Jan-Feb; 19(1):27-31.
    View on PubMed

View on UCSF Profiles